Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Senaparib in mCRPC with HRR gene alterations
NCT04822961Phase 2Unknown
- Sponsor
- IMPACT Therapeutics
- Start
- Dec 2021
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Senaparib with Placebo (2 arms). Primary endpoint: Radiographic Progression-Free Survival at 80 weeks. Status: unknown.
02
Drugs
senaparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04822961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04822961.